| Code | CSB-RA006043MB1HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is designed as a research-grade biosimilar to lacnotuzumab, targeting colony-stimulating factor 1 (CSF1), a critical cytokine that regulates the differentiation, proliferation, and survival of macrophages and monocytes. CSF1 plays a pivotal role in immune homeostasis by binding to its receptor CSF1R, initiating signaling cascades that control myeloid cell populations. Dysregulated CSF1 signaling has been implicated in various pathological conditions, including tumor-associated macrophage accumulation in cancer, where it contributes to immunosuppression and tumor progression, as well as inflammatory and autoimmune disorders.
Lacnotuzumab is a humanized IgG1 monoclonal antibody that neutralizes CSF1 activity, preventing its interaction with CSF1R. This biosimilar antibody provides researchers with a valuable tool for investigating CSF1-mediated pathways in oncology and immunology research, particularly for studying macrophage biology, tumor microenvironment dynamics, and therapeutic strategies targeting myeloid cell populations. It enables exploration of CSF1 blockade mechanisms and supports preclinical studies evaluating immune modulation approaches.
There are currently no reviews for this product.